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Abstract
Purpose/aim:  Glaucoma  consists  of  a  group  of  progressive  optic  neuropathies  that  are  charac-
terized  by  degeneration  of  the  optic  nerve  and  irreversible  visual  ﬁled  loss.  Elevated  intraocular
pressure is  the  only  proven  treatable  risk  factor  and  commercial  products  used  for  glaucoma
treatment are  focused  in  lowering  intraocular  pressure.  These  drugs  can  have  various  undesir-
able side  effects  and  this  invites  to  look  for  new  strategies.  The  purpose  of  this  work  is  to  study
the use  of  a  siRNA  (small  interfering  RNA)  to  selectively  silence  beta2  adrenergic  receptors  and
to see  whether  it  reduces  IOP  (intraocular  pressure).
Material  and  methods:  Topical  instillation  of  beta2  adrenergic  receptors  small-interfering  RNA
(siRNA, 25--250  g)  was  applied  and  IOP  was  measured  with  a  Tonopen  XL  up  to  9  consecutive
days. The  effect  of  such  siRNA  was  compared  to  commercial  compounds  such  as  Timoftlol,  Tru-
sopt and  Xalatan,  and  it  was  also  analyzed  if  some  anatomical  changes  occurred  by  microscopy.
Results: siRNA  designed  for  beta2  adrenergic  receptor  induced  a  reduction  of  intraocular  pres-
sure (IOP)  of  30  ±  5%,  compared  to  a  control  (scrambled  siRNA).  The  results  in  terms  of  IOP
decrease  were  similar  to  that  found  with  commercial  compounds  but  a  long-lasting  hypotensive
action was  shown  by  beta2  adrenergic  receptor  siRNA  treatment  as  compared  to  commercial
drugs. No  apparent  side  effects  were  observed  in  the  ocular  structures.
Conclusion:  The  use  of  siRNA  against  the  beta2  adrenergic  receptors  could  provide  an  interest-
ing therapeutic  strategy  for  glaucoma  treatment.
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Cambio  de  la  presión  intraocular  en  conejos  de  Nueva  Zelanda  mediante
silenciamiento  del  receptor  adrenérgico  Beta2
Resumen
Objetivo:  El  glaucoma  consiste  en  un  grupo  de  neuropatías  ópticas  progresivas  caracterizadas
por degeneración  del  nervio  óptico  y  pérdida  irreversible  del  campo  visual.  La  elevación  de
la presión  intraocular  es  el  único  factor  de  riesgo  tratable  probado,  centrándose  los  produc-
tos comerciales  para  el  tratamiento  del  glaucoma  en  la  reducción  de  la  presión  intraocular.
Estos fármacos  pueden  tener  diversos  efectos  secundarios  indeseados,  lo  cual  invita  a  buscar
nuevas estrategias.  El  objetivo  de  este  trabajo  es  estudiar  el  uso  de  un  ARNip  (ARN  pequen˜o  de
interferencia)  para  silenciar  selectivamente  los  receptores  adrenérgicos  beta2,  y  comprobar  si
reduce la  PIO  (presión  intraocular).
Material  y  métodos:  Se  realizó  instilación  tópica  de  ARN  pequen˜o  de  interferencia  para  los
receptores adrenérgicos  beta2  (ARNip,  25-250  g),  midiéndose  la  PIO  con  Tonopen  XL  hasta
nueve días  consecutivos.  Se  comparó  el  efecto  de  dicho  ARNip  con  componentes  comerciales
tales como  Timoftlol,  Trusopt  y  Xalatan,  analizándose  asimismo  mediante  microscopio  si  se
producía cualquier  cambio  anatómico.
Resultados:  ARNip  disen˜ado  para  el  receptor  adrenérgico  beta2  indujo  una  reducción  de  la
presión intraocular  (PIO)  de  30  ±  5%,  en  comparación  al  control  (ARNip  de  secuencia  aleatoria).
Los resultados  en  términos  de  reducción  de  la  PIO  fueron  similares  a  los  encontrados  utilizando
componentes  comerciales,  aunque  el  tratamiento  con  ARNip  para  el  receptor  adrenérgico  beta2
reﬂejó una  acción  hipotensora  de  larga  duración  en  comparación  con  los  fármacos  comerciales.
No se  observaron  efectos  secundarios  aparentes  en  las  estructuras  oculares.
Conclusión:  El  uso  de  ARNip  contra  los  receptores  adrenérgicos  beta2  podría  aportar  una
estrategia terapéutica  interesante  para  el  tratamiento  del  glaucoma.
© 2017  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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laucoma  consists  of  a  group  of  eye  diseases  showing  a
road  spectrum  of  clinical  presentation  and  unknown  aeti-
logies,  that  lead  to  a  permanent  loss  of  visual  function  due
o  the  death  of  retinal  ganglion  cells  and  damage  of  the  opti-
al  nerve.1 It  is  well  accepted  that  a  critical  risk  factor  in
he  pathogenesis  of  glaucoma  is  the  elevation  in  intraocular
ressure  (IOP)  and  it  is  the  only  proven  treatable  risk  factor.2
IOP  is  generated  and  maintained  by  the  aqueous  humor
irculation  system  in  the  anterior  eye.3 Elevated  IOP  occurs
rom  an  imbalance  between  production  and  outﬂow  of  aque-
us  humor.  The  aqueous  humor  is  a  transparent  nutritional
uid  that  provides  the  nutrients  to  the  inner  avascular
tructures  of  the  eye.4 The  control  of  the  aqueous  humor
roduction  occurs  in  the  ciliary  body  and  it  is  regulated  by
he  sympathetic  nervous  system.5 Noradrenaline  released
rom  the  sympathetic  terminals  stimulate  adrenergic  recep-
ors  that  facilitate  the  production  of  the  aqueous  humor.
his  fact  has  been  taken  by  the  pharmaceutical  companies  to
evelop  a  series  of  antagonists  of  mainly  2-adrenoceptors
o  reduce  aqueous  humor  production,  reducing  IOP  in
laucoma.6 Other  drugs  currently  used  to  decrease  the  rate
f  aqueous  humor  inﬂow  are  carbonic  anhydrase  inhibitors
6Please  cite  this  article  in  press  as:  Loma  P,  et  al.  Beta2  adrene
Zealand  rabbits.  J  Optom.  (2017),  http://dx.doi.org/10.1016/
nd  1-adrenoceptor  agonists. Additionally,  there  are  phar-
acological  agents  such  as  cholinoceptor  agonists  and
rostaglandin  analogs  that  lower  IOP  by  increasing  the  rate
f  aqueous  humor  outﬂow.7,8
t
v
c
eThus,  pharmacological  reduction  of  IOP  by  decreasing
he  rate  of  aqueous  humor  inﬂow  or  increasing  the  rate
f  aqueous  outﬂow  is  the  current  therapeutic  approach
or  preserving  visual  function  in  glaucoma  patients.  How-
ver,  all  the  pharmacological  agents  mentioned  can  have
arious  undesirable  effects.  For  instance,  2-adrenoceptors
lockers  can  cause  substantial  cardiovascular  and  respira-
ory  side  effects,8 carbonic  anhydrase  inhibitors  use  must
e  restricted  in  subjects  with  renal  disease  and  patients
ith  compromised  endothelium,9 prostaglandin  analogs  can
riginate  conjunctival  hyperaemia,  lengthening  and  thick-
ning  of  eyelashes  or  changes  in  eye  color.10 Moreover,  the
fﬁcacy  of  these  drugs  is  also  likely  to  be  reduced  after  pro-
onged  use.1 Thus,  there  is  the  need  to  discover  novel  agents
rom  the  presently  available  pharmacological  classes.  In
his  context,  RNA  interference-based  therapy  for  glaucoma
an  be  an  attractive  alternative  approach.  RNA  interfer-
nce  involves  speciﬁc  gene  expression  silencing  by  small
olecules  of  double  stranded  RNA:  small  interference  RNAs
siRNAs).11
The  eye  is  currently  considered  a  good  target  for  RNAi
herapy  mainly  because  it  is  an  accessible  and  conﬁned
ompartment.  The  accessibility  of  the  eye  facilitates  siRNA
elivery,  and  naked  siRNAs  have  been  efﬁciently  applied  byrgic  receptor  silencing  change  intraocular  pressure  in  New
j.optom.2017.08.002
opical  administration  to  the  anterior  segment  or  by  intra-
itreal  injection  to  the  posterior  segment.12 In  addition,  its
onﬁned  location  provides  several  advantages.  Local  deliv-
ry  of  compounds  to  the  eye  restricts  systemic  exposure  and
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Beta2  adrenergic  receptor  silencing  change  intraocular  pres
reduces  the  amount  of  compound  needed  diminishing  poten-
tial  side  effects  outside  the  eye.  Moreover,  the  immune
system  has  a  limited  access  to  the  eye;  therefore  immune
responses  to  the  compound  are  less  likely  to  occur.13
As  the  localized  delivery  of  siRNA  to  the  eye  is  less  chal-
lenging  than  for  other  tissues,  there  has  been  signiﬁcant
progress  made  toward  its  use  as  a  therapeutic  procedure
for  eye  diseases.14 In  fact,  several  siRNA-based  therapeutic
agents  for  ocular  disorders  such  as  wet  age-related  macular
degeneration  and  diabetic  retinopathy  have  already  reached
clinical  trials.15--17
In  the  present  work,  we  analyze  the  use  of  siRNA,
designed  to  silence  2-adrenoceptors,  in  order  to  reduce
IOP  in  rabbits,  studying  the  characteristics  of  different  con-
centrations  of  siRNA  on  the  animal  responses  and  comparing
this  novel  strategy  with  classical  glaucoma  treatments.
Materials and methods
Animals
24  male  normotensive  New  Zealand  white  rabbits,  with
6--8  weeks  of  age,  were  kept  in  individual  cages  with  food
and  water  ad  libitum  and  maintained  under  a  controlled
12  h/12  h  light/dark  cycles.  All  the  procedures  complied
with  the  ARVO  Statement  for  the  Use  of  Animals  in  Ophthal-
mology  and  Vision  Research.  Animal  studies  were  approved
by  the  Ethical  Committee  of  Complutense  University  (UCM-
CEA)  which  follows  the  tenets  of  the  European  Communities
Council  Directive  (86/609/EEC).
siRNA  and  commercial  drug  application
All  the  siRNA  experiments  were  performed  and  measured
at  the  same  time.  A  siRNA  targeting  the  beta2  adrener-
gic  receptor  (sc-39866)  and  siRNA  scramble  (sc-37007)  were
purchased  from  Santa  Cruz  (Hercules,  CA,  USA).
The  siRNAs  were  topically  applied  in  one  eye  and  the  con-
tralateral  eye  received  the  same  volume  of  saline  solution
(0.9%  NaCl).  The  single  eye  treated  with  the  siRNAs  received
an  amount  of  250  g  of  the  siRNA  dissolved  in  40  L of  0.9%
NaCl,  daily  in  a  single  dose  on  four  consecutive  days.  For
dose--response  studies,  concentrations  of  125  g,  and  25  g
were  dissolved  in  40  L  of  0.9%  NaCl.  Experiments  were
performed  using  a  single  blind  design:  no  visible  indication
was  given  to  the  experimenter  as  to  the  applied  solution
(agent  or  vehicle).  IOP  was  measured  for  more  than  8  days
and,  afterwards,  animals  were  killed  and  both  eyes  were
collected.
In  the  experiments  performed  with  commercially  avail-
able  drugs  40  L  of  the  commercial  drugs:  Trusopt
(dorzolamide)  (Merck  Sharp  &  Dohme  de  Espan˜a S.A.,
Madrid,  Spain),  Xalatan  (latanoprost)  (Pﬁzer,  Alcobendas,
Madrid,  Spain)  and  Timoftol  (timolol)  (Santen  Oy,  Tampere,
Finlandia)  were  instilled  daily  over  a  period  of  four  consec-
utive  days.  IOP  levels  of  rabbits  treated  with  commercialPlease  cite  this  article  in  press  as:  Loma  P,  et  al.  Beta2  adrener
Zealand  rabbits.  J  Optom.  (2017),  http://dx.doi.org/10.1016/
drugs  or  with  siRNAs  were  measured  every  hour  for  a  total
of  8  h,  starting  1  h  after  the  last  administration.  In  addition,
to  estimate  the  mean  time  effect  of  these  compounds,  IOP
was  also  measured  for  8  days  as  described  above.
T
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t PRESS
 in  rabbits  3
ntraocular  pressure  (IOP)  measurements  in  rabbits
OP  was  measured  by  means  of  a  Tono-Pen  XL  contact
onometer  (Mentor  Massachusetts  Inc.,  Norwell,  MA).
opical  anesthesia  (Colircusi,  Laboratorios  Cusi,  Spain:
.1  mg/ml  tetracaine  plus  0.4  mg/ml  oxybuprocaine  in  0.9%
aline,  diluted  1:3  in  0.9%  saline)  was  applied  (10  L)  to  the
ornea  before  each  measurement  to  avoid  animal  discom-
ort.
ide  effects
he  assessment  of  the  ocular  tolerance  of  the  RNAi
equences,  were  followed  several  aspects  and  parameters
rom  the  tear  ﬁlm,  ocular  anexa  and  ocular  surface.  The
nalysis  were  performed  and  graded  before  and  after  the
opical  application  of  siRNA  with  the  Efron  grading  scales.
 Topcon  SL-8Z  slit  lamp  and  a  Topcon  SP-2000P  specular
icroscope  (Topcon  Spain,  Madrid,  Spain),  as  well  as  a  dig-
tal  camera  and  a  ‘‘de  visu’’  exam  were  used  for  every
xperiment.  Slit-lamp  images  were  captured  under  10×  aug-
ents,  a  diffuser  ﬁlter  and  a  medium  degree  of  illumination.
he  images  were  recorded  and  analyzed  by  IMAGEnet  2000
ystem  software  (Topcon).
ata  analysis
ll  data  are  presented  as  the  mean  ±  S.E.M.  Signiﬁcant  dif-
erences  were  determined  by  two-tailed  Student’s  t-tests.
he  plotting  and  ﬁtting  of  all  the  data  was  carried  out  with
he  computer  program  Prism  GraphPad  v.4.0  (Prism,  USA).
esults
ffect  and  speciﬁcity  of  beta2  adrenergic  siRNA  on
OP
he  effect  of  a  siRNA  designed  for  silencing  the  beta2  adren-
rgic  receptor  was  tested  together  with  a  scramble  siRNA
n  order  to  conﬁrm  the  speciﬁcity  of  the  tested  siRNA.  Mea-
urement  of  intraocular  pressure  (IOP)  was  monitored  during
ore  than  8  days  applying  both  siRNA  under  the  conditions
escribed  in  methods  (250  g  of  the  siRNA  in  40  L).
As  observed  in  Fig.  1, whereas  beta2  adrenergic  recep-
or  siRNA  application  clearly  induced  a  hypotensive  effect
educing  IOP  74.0  ±  2.0%  (n  =  8),  after  the  treatment  with
he  scramble  siRNA,  rabbit  IOP  did  not  signiﬁcantly  change
uring  the  time  of  the  experiment,  conﬁrming  both  the
ffect  and  the  speciﬁc  action  of  beta2  adrenergic  recep-
or  siRNA.  Concerning  the  mean  time  effect  (duration  of  the
ffect),  the  application  of  the  aforementioned  siRNA  pro-
uced  a  maximal  effect  that  lasted  for  about  120  h  (Table  1).
ffect  of  different  doses  of  beta2  adrenergic
eceptor  siRNAs  on  IOPgic  receptor  silencing  change  intraocular  pressure  in  New
j.optom.2017.08.002
o  see  whether  the  silencing  of  beta2  adrenergic  receptors
roduced  changes  in  the  IOP  when  different  doses  were
pplied,  the  rabbits  were  treated  with  the  siRNAs  against
he  beta2  adrenergic  receptor  and  monitored  in  their  IOP
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Figure  1  Comparative  time-course  of  changes  in  intraocu-
lar pressure  in  response  to  beta2  adrenergic  receptor  siRNA
and scramble  siRNA.  Effects  of  scramble  siRNA  (ﬁlled  circles)
and beta2  adrenergic  receptor  siRNA  (open  circles)  on  intraoc-
ular  pressure  were  followed  for  216  h.  100%  represents  the
intraocular  pressure  before  the  application  of  siRNAs  which  cor-
responded  to  a  IOP  of  15.2  ±  1.8  mm  Hg.  Values  represent  the
mean  ±  S.E.M.  (n  =  8).
Table  1  Mean  time  effect  of  the  tested  compounds.
Compound  Mean  time  effect
siRNA  (250  g)  120  h
siRNA  (125  g)  96  h
siRNA  (25  g)  78  h
Xalatan  6  h
Trusopt  5  h
Timoftol  7  h
The mean time effect of each dose of beta2 adrenergic receptor
siRNA as well as the commercial drugs Xalatan, Trusopt and Tim-
oftol was calculated as the difference between the half maximal
time-point of recovery and the time at which the half maximal
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Figure  2  Effect  of  siRNAs  on  intraocular  pressure.  (A)  Time-
course of  changes  in  intraocular  pressure  in  response  to  siRNAs
instillation.  Effects  of  siRNAs  at  different  concentrations  on
intraocular  pressure  were  followed  for  216  h.  (B)  Comparison
between  the  maximal  effects  obtained  for  the  siRNAs.  100%  rep-
resents the  intraocular  pressure  before  application  of  siRNAs.
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Commercial  drugs  showed  mean  time  effect  values  between
5  and  7  h,  whereas  the  effect  of  the  beta2  adrenergic  recep-effect on IOP was achieved.
or  more  than  8  days.  Three  different  concentrations  of
he  beta2  adrenergic  receptor  siRNA  were  tested:  250  g,
25  g  and  25  g,  dissolved  in  40  L  of  0.9%  NaCl  (Fig.  2).
s  it  shown  in  Fig.  2A  the  lowest  dose  of  siRNA  tested  only
nduced  a  slight  modiﬁcation  in  IOP  with  a  reduction  of  8%
02  h  after  application.  The  dose  of  125  g  evoked  an  IOP
ecrease  of  around  10%  at  24  h,  with  the  highest  effect  (14%
f  reduction)  observable  60  h  after  application  and  sustained
n  the  next  24  h.
The  highest  dose  of  beta2  adrenergic  receptor  siRNA
250  g),  induced  a  robust  reduction  in  IOP  which  started
o  be  measurable  24  h  after  the  instillation  of  the  siRNA
nd  which  was  statistically  signiﬁcant  for  5  days.  The  max-
mal  reduction  obtained  after  silencing  the  beta2  receptor
as  30  ±  5%  compared  to  control.  This  and  similar  values
ere  maintained  for  1--2  days,  with  the  IOP  remaining  low
or  three  more  days  (with  a  mean  of  30%  of  reduction)  and
hen  returning  slowly  toward  control  values  (Fig.  2A).  The
aximal  reduction  in  IOP  obtained  for  each  given  dose  is
resented  in  Fig.  2B,  where  it  can  be  seen  that  the  reduc-Please  cite  this  article  in  press  as:  Loma  P,  et  al.  Beta2  adrene
Zealand  rabbits.  J  Optom.  (2017),  http://dx.doi.org/10.1016/
ion  of  IOP  is  dependent  of  the  doses  assayed.  Interestingly,
t  was  possible  to  observe  that  the  higher  the  dose  of  beta2
t
7alues  represent  the  mean  ±  S.E.M.  (n  =  8,  *p  <  0.05,  **p  <  0.01,
**p <  0.001  vs.  control).
drenergic  receptor  siRNA  was  applied  the  longer  mean-time
ffect  was  obtained  (Table  1).
omparative  studies  with  commercial  drugs
he  effect  of  beta2  adrenergic  receptor  siRNA  on  IOP  of  New
ealand  White  rabbits  was  compared  with  that  induced  by
phthalmic  commercial  drugs:  Trusopt  (dorzolamide),  Xala-
an  (latanoprost)  and  Timoftol  (timolol).  As  observed  in
ig.  3, any  of  those  compounds  produced  a  decrease  in  IOP
f  between  20  and  35%,  this  reduction  in  IOP  was  similar  to
hat  found  with  beta2  adrenergic  receptor  siRNA  treatment.
In  addition,  the  effect  of  the  beta2  adrenergic  receptor
iRNA  in  terms  of  time  effect  was  also  compared  with  con-
entional  pharmacological  agents  and  the  mean  time  effect
f  each  compound  was  calculated  as  the  difference  between
he  half  maximal  time-point  of  recovery  and  the  time  at
hich  the  half  maximal  effect  on  IOP  was  achieved  (Table  1).rgic  receptor  silencing  change  intraocular  pressure  in  New
j.optom.2017.08.002
or  siRNA  was  signiﬁcantly  longer  exhibiting  values  between
8  and  120  h for  the  higher  doses  assayed.
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Figure  3  Maximal  IOP  reduction  elicited  by  siRNA  against  the
beta2 adrenergic  receptor  and  anti-glaucomatous  drugs.  Maxi-
mal IOP  reduction  (%  of  control)  for  beta2  adrenergic  receptor
siRNA tested  (250  g)  was  compared  with  the  hypotensive  action
induced  by  Xalatan,  Trusopt  and  Timoftol.  Control  (100%)  repre-
sents the  intraocular  pressure  before  the  application  of  any  drug
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and  accordingly  they  are  not  biologically  active.  In  addition,
the  analysis  of  several  parameters  (clinical  signs,  electro-(15.2 ±  1.8  mm  Hg).  Values  represent  the  mean  ±  S.E.M.  (n  =  8).
Discussion
Glaucoma  is  one  of  the  leading  causes  of  blindness  in  the
world.  Anti-glaucomatous  drugs  currently  prescribed  can
have  various  undesirable  effects  and  their  efﬁcacy  is  also
subject  to  a  reduction  after  prolonged  use.1 Moreover,  to
maintain  adequate  levels  of  IOP,  frequent  instillation  is  nec-
essary,  which  can  lead  to  poor  compliance  of  the  patient.
Therefore,  the  development  of  new  therapeutic  strategies
to  circumvent  the  drawbacks  associated  to  the  presently
available  pharmacologic  classes  is  required.  In  this  context,
we  analyzed  siRNA-based  therapy  for  glaucoma.
In  particular,  we  focused  our  attention  on  beta2  adrener-
gic  receptors,  since  their  commercial  inhibitors  are  effective
in  lowering  IOP,  the  primary  indication  of  glaucoma.6 The
hypotensive  action  of  a  commercial  sequence  of  beta2
adrenergic  receptor  siRNA  was  tested  in  rabbits.  The  results
conﬁrmed  the  reduction  of  the  IOP  in  rabbits,  in  a  marked
and  sustained  way.  The  frequency  of  application  is  a  factor
to  be  considered  to  achieve  this  IOP  reduction  in  a  repro-
ducible  mode.  In  this  case,  beta2  adrenergic  receptor  siRNA
was  administered  daily  in  a  single  dose  on  four  consecutive
days  in  rabbits.  This  approach,  the  use  of  siRNA  to  reduce
IOP  has  been  also  observed  by  other  authors,  with  similar
results  to  the  ones  here  presented.18,19 In  a  clear  difference
with  those  works,  the  reduction  in  IOP  observed  at  the  high-
est  siRNA  concentration  showed  a  decreased  in  IOP  around
30%  while  in  the  work  by  Moreno-Montan˜es  and  co-workers
it  only  reduced  around  20%.19 Also,  the  concentrations  used
by  these  authors,  up  to  900  g/day  are  far  from  the  doses
here  studied,  which  were  250  g/day.  The  present  study  was
performed  in  rabbits  while  the  one  of  900  g/day  was  car-
ried  out  in  humans.  Although  the  aqueous  humors  in  rabbits
and  humans  are  not  so  different,  it  would  be  interesting  toPlease  cite  this  article  in  press  as:  Loma  P,  et  al.  Beta2  adrener
Zealand  rabbits.  J  Optom.  (2017),  http://dx.doi.org/10.1016/
carry  out  experiments  in  humans  to  conﬁrm  the  potential
higher  efﬁcacy  of  the  siRNA  used  in  our  work.
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The  value  of  IOP  reduction  obtained  using  siRNA  was
imilar  to  that  found  with  drugs  currently  prescribed  for
laucoma  treatment  such  as  Xalatan,  Trusopt  or  Timoftol.
lthough  the  recommended  dosage  for  Trusopt  or  Timoftol
n  some  patients  is  one  drop  in  the  affected  eye  twice  a  day,
e  administrated  these  drugs  following  similar  experimen-
al  conditions  than  those  used  for  siRNA  application  (a  daily
ingle  dose  on  four  consecutive  days).  Clearly,  differences  in
pplication  frequency  of  therapies  can  have  inﬂuence  in  the
esults.  In  order  to  compare  the  hypotensive  effect  induced
y  siRNA  treatment  with  the  effect  produced  by  drugs  we
sed  the  same  dosage  regimen.
The  effect  of  beta2  adrenergic  siRNA  treatment  was  sig-
iﬁcantly  longer  in  terms  of  time-effect  as  compared  to
onventional  pharmacological  agents.  While  the  commer-
ial  compounds  reduced  IOP  for  a  few  hours,  the  siRNA  effect
asted  for  several  days.  In  a  previous  study,18 a single  dose  of
 siRNA  for  the  beta  receptor,  provided  a  mean  time  effect
f  91  h,  while  in  our  case  it  was  about  120  h.  Therefore,
t  seems  that  comparing  commercial  compounds  as  well  as
ther  siRNA  treatments  already  published,  it  seems  that  the
haracteristics  of  the  sequence  we  use  is  also  better  pro-
ucing  a  longer  lasting  effect.
Comparing  to  the  commercial  drugs,  it  is  a  clear  that
iRNA  effect,  which  uses  a  different  molecular  mechanism
o  those  used  by  commercial  medicines,  provide  a  more  pro-
ound  and  sustained  reduction  in  IOP.  When  RNAi  therapy
s  used,  upon  cessation  of  treatment  the  silenced  protein
as  to  be  re-synthesized  in  order  to  recover  its  activity  and
onsequently  it  prolong  the  duration  of  the  treatment  as
ompared  to  conventional  treatments.  Thus,  siRNA  against
eta2  adrenergic  receptor  enables  to  obtain  a  signiﬁcant
eduction  in  IOP  with  a  long-term  effect,  whereas  continu-
us  application  of  commercial  drugs  would  be  necessary  to
nduce  a  sustained  effect  on  IOP.
This  long-lasting  reduction  of  IOP  may  be  one  of  the  most
ttractive  features  of  this  new  approach  for  the  treatment
f  ocular  hypertension  and  glaucoma  since  it  could  allow
educing  the  frequency  of  instillation  and  improving  patient
ompliance.  Moreover,  taking  into  account  that  the  frequent
pplication  of  some  commercial  drugs  currently  used  at  high
oncentrations  to  achieve  the  desired  therapeutic  effects,
an  lead  to  adverse  side  effects  due  to  systemic  absorp-
ion  (e.g.,  timolol  can  generate  deleterious  effect  in  the
eart)8 the  use  of  siRNA  therapy  could  minimize  these  side
ffects.  Likewise,  it  has  been  demonstrated  that,  on  the
ontrary  to  an  isolated  compartment  as  the  eye,  siRNA  sta-
ility  in  serum  is  decreased  as  a consequence  of  RNases
ctivity.18 Thus,  a  reduced  siRNA  half-life  in  serum  also
ould  contribute  to  reduce  the  likelihood  of  systemic  side
ffects.  A  potential  limitation  of  our  study  is  that  we  have
ot  evaluated  those  possible  systemic  side  effects.  However,
revious  reports  suggest  the  safety  of  siRNA  treatment.  In
nimal  biodistribution  studies18 only  trace  amounts  of  siRNA
ere  detected  in  systemic  organs  (lung,  liver  and  kidney)
nd  the  absence  of  5′-phosphorylated  antisense  strand  of
iRNA  (a  marker  of  intracellular  delivery  of  the  siRNA)  indi-
ated  that  the  siRNAs  were  not  internalized  by  the  cellsgic  receptor  silencing  change  intraocular  pressure  in  New
j.optom.2017.08.002
ardiogram,  hematology)  in  toxicity  studies  performed  with
nimals  that  received  ocular  administration  of  siRNA  did
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ot  reveal  any  alterations,  indicating  the  safety  of  siRNA
reatment.18 Supporting  these  data,  in  a  study  with  humans
sing  a  siRNA  targeting  the  2  adrenergic  receptor,19 no  sig-
iﬁcant  changes  were  observed  during  the  comprehensive
linical  evaluations,  monitoring  of  vital  signs  or  electrocar-
iograms.
On  the  other  hand,  although  the  eye  content  of  RNases  is
ower  than  in  other  tissues  and,  indeed,  a  long-lasting  effect
as  achieved  by  simple  topical  administration  of  a  naked
iRNA,  perhaps  the  use  of  a  non-viral  vector  carrier,  preven-
ing  siRNA  degradation,  could  even  prolong  the  hypotensive
ction  of  the  siRNA.  Finally,  the  siRNA  application  did  not
lter  the  integrity  of  ocular  structures  and  neither  other
cular  side  effects  were  observed.
In  summary,  our  results  support  a  new  generation  of
rugs  to  treat  ocular  hypertension  and  glaucoma  based  on
NAi  therapy,  which  allows  targeting  of  speciﬁc  sequences
f  single  genes  and  local  delivery  into  the  eye.  The  long-
erm  effect  on  IOP  reduction  induced  by  siRNA  could
ake  possible  to  reduce  the  dose  of  siRNA  minimizing
ide  effects  in  other  tissues  as  well  as  simplifying  patient
ompliance.
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